Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Sangart Inc
Profile last edited on: 8/8/12      CAGE: 4JQ20      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1998
First Award
1999
Latest Award
2004
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

6175 Lusk Boulevard
San Diego, CA 92121
   (858) 450-2400
   sangartinfo@sangart.com
   www.sangart.com
Location: Multiple
Congr. District: 52
County: San Diego

Public Profile

Sangart, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of oxygen therapeutics. It offers Hemospan, a human hemoglobin-based product that delivers oxygen to tissues at risk of oxygen deprivation. The company’s MP4CO, a biopharmaceutical product is used for the treatment of acute painful sickling crises in patients with sickle cell diseas

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$338,247
Phase II Dollars
$970,714
Total Awarded
$1,308,961

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2004 1 NIH $133,303
Project Title: Instrument to Measure Oxygen Affinity of Hemoglobin
2001 2 NIH $1,070,299
Project Title: Novel Peg Hemoglobin Modification For Blood Replacement
1999 1 NIH $105,359
Project Title: Instrument To Characterize Cell-Free 02 Carriers

Key People / Management

  Brian O'Callaghan -- CEO & President

  Robert Winslow -- former President

Company News

There are no news available.